Price$0.49-0.81 (-61.92%)
2026-03-052026-06-08
News · 26 weeks18-100%
2025-12-142026-06-07
Mix1390d
- SEC Filings7(54%)
- Insider3(23%)
- Other3(23%)
Latest news
25 items- INSIDERDirector Smith W Bradford returned 640 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
- SECSEC Form 15-12G filed by Lyra Therapeutics Inc.15-12G - Lyra Therapeutics, Inc. (0001327273) (Filer)
- SECSEC Form 25 filed by Lyra Therapeutics Inc.25 - Lyra Therapeutics, Inc. (0001327273) (Filer)
- SECSEC Form 8-K filed by Lyra Therapeutics Inc.8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)
- PRLyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SECWATERTOWN, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (the "Company") today announced its intention to voluntarily file a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission (the "SEC") on Monday, April 20, 2026, to remove its common stock from listing and registration on The Nasdaq Stock Market LLC ("Nasdaq"). As previously disclosed, trading in the Company's common stock was suspended by Nasdaq on March 17, 2026. Although Nasdaq has indicated it intends to file its own Form 25 after all internal procedural periods have run, it has not yet done so. The Company is therefore voluntarily filing Form 25 in order to proceed with deregistrat
- SECSEC Form 8-K filed by Lyra Therapeutics Inc.8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)
- INSIDERSEC Form 4 filed by Palasis Maria4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
- INSIDERSEC Form 4 filed by Cavalier Jason4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
- SECSEC Form 10-K filed by Lyra Therapeutics Inc.10-K - Lyra Therapeutics, Inc. (0001327273) (Filer)
- SECSEC Form EFFECT filed by Lyra Therapeutics Inc.EFFECT - Lyra Therapeutics, Inc. (0001327273) (Filer)
- SECSEC Form EFFECT filed by Lyra Therapeutics Inc.EFFECT - Lyra Therapeutics, Inc. (0001327273) (Filer)
- SECSEC Form EFFECT filed by Lyra Therapeutics Inc.EFFECT - Lyra Therapeutics, Inc. (0001327273) (Filer)
- SECSEC Form 8-K filed by Lyra Therapeutics Inc.8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)
- SECSEC Form 8-K filed by Lyra Therapeutics Inc.8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)
- SECSEC Form 8-K filed by Lyra Therapeutics Inc.8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)
- SECLyra Therapeutics Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)
- INSIDERChief Financial Officer Cavalier Jason sold $2,587 worth of shares (769 units at $3.36), decreasing direct ownership by 0.15% to 518,547 units (SEC Form 4)4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
- INSIDERPresident & CEO Palasis Maria sold $5,726 worth of shares (1,702 units at $3.36), decreasing direct ownership by 0.15% to 1,096,733 units (SEC Form 4)4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Lyra Therapeutics Inc.SCHEDULE 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Lyra Therapeutics Inc.SCHEDULE 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)
- INSIDERLarge owner Perceptive Advisors Llc sold $182,515 worth of shares (45,875 units at $3.98) (SEC Form 4)4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Lyra Therapeutics Inc.SCHEDULE 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)
- SECSEC Form 10-Q filed by Lyra Therapeutics Inc.10-Q - Lyra Therapeutics, Inc. (0001327273) (Filer)
- SECLyra Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)
- INSIDERLarge owner Perceptive Advisors Llc sold $344,219 worth of shares (70,390 units at $4.89) (SEC Form 4)4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
LYRA FAQ
7 questionsWhat does Lyra Therapeutics Inc. do?
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients...Where does LYRA stock trade?
Lyra Therapeutics Inc. (LYRA) is listed on NASDAQ.What sector and industry is LYRA in?
Lyra Therapeutics Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Lyra Therapeutics Inc. go public?
Lyra Therapeutics Inc. (LYRA) completed its IPO in 2020.What are analysts saying about LYRA?
Lyra Therapeutics Inc. has had 7 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral with a $200.00 price target on 2024-05-07.What companies are similar to LYRA?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare LYRA side-by-side with any of them on Quantisnow.How can I track LYRA on Quantisnow?
Quantisnow aggregates Lyra Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LYRA to receive live email and push alerts on every new disclosure.